Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Saunte, Ditte Marie
  • M. Pereiro-Ferreirós
  • C. Rodríguez-Cerdeira
  • A. Y. Sergeev
  • M. Arabatzis
  • A. Prohić
  • B. M. Piraccini
  • P. Lecerf
  • P. Nenoff
  • L. P. Kotrekhova
  • P. P. Bosshard
  • V. Padovese
  • J. C. Szepietowski
  • B. Sigurgeirsson
  • R. J. Nowicki
  • P. Schmid-Grendelmeier
  • R. J. Hay

Background: Dermatophytosis is a world-wide distributed common infection. Antifungal drug resistance in dermatophytosis used to be rare, but unfortunately the current Indian epidemic of atypical widespread recalcitrant and terbinafine-resistant dermatophytosis is spreading and has sporadically been reported in Europe. Objectives: To explore the occurrence of clinical and mycological proven antifungal drug resistance in dermatophytes in Europe. Methods: A standardized questionnaire was distributed through the EADV Task Force of Mycology network to dermatologists in Europe. Results: Representatives from 20 countries completed the questionnaires of which 17 (85 %) had observed clinical and/or mycological confirmed antifungal resistance, two countries published cases of antifungal resistance and one country had no known cases. Conclusions: This pilot study confirms that both clinical and mycological antifungal resistance exist in Europe.

OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology
Vol/bind35
Udgave nummer7
Sider (fra-til)1582-1586
ISSN0926-9959
DOI
StatusUdgivet - 2021

ID: 261056082